From $617 to $350: CVS Sets "Break-Even Price" for Weight-Loss Drugs, Says Pharmaceutical Companies Can Still Profit

According to information from the Zhihui Finance APP, an analysis of insurance claims data has found that if GLP-1 drugs used for weight loss and diabetes are priced below $350 per month, payers—such as employers and plan sponsors—will achieve net savings due to decreased use of related medical services.

This analysis was conducted by CVS Health, based on claims data from recent patients who started using these drugs through its insurance subsidiary Aetna. Eli Lilly (LLY.US) sells Zepbound (tirzepatide) for obesity and Mounjaro (tirzepatide) for type 2 diabetes; Novo Nordisk (NVO.US) sells Wegovy (semaglutide) for weight loss and Ozempic (semaglutide) for diabetes, respectively.

The gap between current prices and the “break-even point”

According to a report by the Employee Benefit Research Institute (EBRI) in October 2025, the average monthly cost paid by employers and health plan sponsors for GLP-1 drugs ranges between $617 and $766. At this level, the drug costs cannot be offset by the medical savings resulting from reduced healthcare service usage.

Eli Lilly and Novo Nordisk currently offer GLP-1 drugs to self-pay customers at a range of $299 to $499 per month (depending on dosage)—which is close to, but not yet generally below, the $350 threshold.

CVS Health’s Chief Medical Officer Amy Compton-Phillips told Reuters that she believes pharmaceutical companies can remain profitable even if they sell at a price below $350 per month.

This analysis will be released at the HLTH USA conference in Las Vegas on Sunday.

Why this analysis is worth attention

For employers and insurance plans, GLP-1s have always presented a dilemma: while the drug cost alone represents a significant expense, reductions in weight-related complications, hospitalizations, and surgical requirements could mean that the long-term total cost is actually lower. In fact, CVS’s analysis provides a pragmatic pricing benchmark for this debate—$350 per month.

This statement also comes at a key moment for CVS itself: the company just announced last week that it will split into two companies in the first half of 2028, with Aetna and Caremark (PBM) remaining with CVS Health, and the retail pharmacy business operating independently. As an integrated group controlling insurance (Aetna), pharmacy benefit management (Caremark), and a pharmacy network, CVS’s position on GLP-1 pricing naturally carries the weight of a “buyer’s bargaining power.”